1	Comprehensive analysis of prostate cancer life expectancy, loss of life
2	expectancy, and healthcare expenditures: Taiwan national cohort
3	study spanning 2008 to 2019
4	
5	Prostate cancer life expectancy, loss of life expectancy, and
6	healthcare expenditures in Taiwan
7	
8	
9	Pin-Chun Liu ¹ ¶, Yi-Sheng Lin ¹ ¶, Yen-Chuan Ou ^{1*} , Chao-Yu Hsu ^{1&} , Min-Che Tung ^{1&} ,
10	Ying-Ming Chiu ^{2,3,4} ¶
11	
12	¹ Division of Urology, Department of Surgery, Tungs' Taichung Metroharbor Hospital,
13	Taichung City, Taiwan
14	² Departments of Allergy, Immunology, and Rheumatology, Tungs' Taichung MetroHarbor
15	Hospital, Taichung City, Taiwan
16	³ Departments of big data research center, Tungs' Taichung MetroHarbor Hospital, Taichung
17 N	City, Taiwan OTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

18	⁴ Departments of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing
19	University, Taichung City, Taiwan
20	
21	
22	* Corresponding author
23	E-mail: ycou228@gmail.com (YCO)
24	
25	
26	[¶] These authors contributed equally to this work.
27	^{&} These authors also contributed equally to this work.
28	
29	
30	
31	
32	
33	

34

35 Abstract

37	Prostate cancer (PCa) is the second most commonly diagnosed cancer worldwide and the 5th
38	leading cause of death from cancer for men in Taiwan. The incidence of synchronous
39	metastatic PCa in Taiwan is higher than U.S. and Europe. We aim to present the latest life
40	expectancy (LE), loss of LE, and lifetime cost associated with PCa in Taiwan. The PCa data
41	are based on Taiwan Cancer Registry and National Health Insurance Database. Total 30,207
42	new cases of PCa were recorded during 2008-2019 nationwide. LE, estimated loss of LE and
43	lifetime cost were stratified by age, cancer stage, Gleason score, grade group and serum PSA
44	level at diagnosis. We compared LE and healthcare cost outcomes between synchronous
45	metastatic PCa patients in 3 age groups. Among the 30,207 new cases, the low to intermediate
46	risk groups, high-risk groups, and regional and metastatic PCa accounted for 54.1%, 13.2%,
47	and 32.6% of cases, respectively. A considerable proportion of synchronous metastatic PCa
48	was noted in Taiwan when compared with the U.S. For synchronous metastatic PCa, the
49	highest LE is 9.22 years for ages 20-64 years, followed by ages 65-74 (8.29 years) and ages
50	75-89 years (4.58 years). The loss of LE in the three groups is 13.63, 6.75, and 3.87 years,
51	respectively. The healthcare cost of synchronous metastatic PCa in all age groups is higher
52	than the average cost for PCa patients in Taiwan. This study provides real-world evidence to

53	support health care policy-making and clinical decisions regarding PCa. Due to the high
54	proportion of synchronous metastatic PCa in Taiwan, the findings of this analysis emphasize
55	the importance of early detection of PCa, which can save LE and decrease the total cost
56	burden on the healthcare system.
57	

58 Introductions

60	Prostate cancer (PCa) was the cancer with the highest incidence for men in 114 countries and
61	the leading cause of cancer-related deaths among men in 56 countries in 2017 [1]. It
62	accounted for 191,930 new cases and 33,330 deaths among U.S. males in 2020. From 2012 to
63	2017, the incidence of PCa in the United States was 104.1 per 100,000 people, with a
64	mortality rate of 19.1 per 100,000 people [2]. In Taiwan, PCa was responsible for the fifth
65	cancer cause of death among male based on the statistics of cause of death in 2019 announced
66	by the ministry of health and warfare. The estimated crude death rate caused by PCa is 13.1
67	per 100,000 persons [3]. Statistics indicate a progressive increase in the incidence rate of PCa
68	in Taiwan. Overall, the age-standardized incidence of PCa between 2008 and 2019 increased
69	by 11.22% (from 24.61 to 35.83 per 100,000 people). The accurate reason could be
70	complicated and multifactorial; proposed explanations include an aging population, the

71	popularization of blood tests, westernized diets, and lifestyle alterations. A previous study
72	revealed a wide variation in the incidence and mortality rates of PCa in Asians. Compared
73	with other Asian countries, the incidence of PCa in Taiwan is second only to Australia, New
74	Zealand, and Turkey. [4].
75	The treatment of PCa imposed a great impact on both individuals and the country's financial
76	burden. Gustavsen, Gary et al. indicated that the cumulative cost of managing localized PCa
77	on a per-patient was estimated to be USD \$46,193 over 5 years and USD \$110,993 over 10
78	years [5]. Smith-Palmer, J et al. mentioned that total overall cost in the first year after
79	diagnosis of PCa was EUR 385 million in France, followed by EUR 244 million in Germany
80	and then the United Kingdom at EUR 117 million per year in 2006 [6]. PCa also causes a
81	great number of deaths worldwide annually. A study by Withrow, Diana et al. mentioned that
82	3.5 million person-years of life were lost due to PCa in males over 50, with 40% of years of
83	life lost occurring in those aged over 75 [7].
84	However, most of the previous studies are based on materials and documents from Western
85	countries. Hwang et al. developed a novel semiparametric method to improve the accuracy of
86	estimates of life expectancy (LE) and loss of life expectancy (loss of LE) from the date of
87	diagnosis [8-9]. In this study, we estimated the PCa patients LE, loss of LE and lifetime
88	health care expenditures, stratified by age and stage in the Taiwanese population with up to
89	12 years of follow-up.

90

91 Materials and Methods

93	We identified a study cohort by using the database of Taiwan Cancer Registry (TCR)
94	database from 2011 to 2017, and patients with PCa were identified by ICD-O-3 topography
95	code: C61.9. Patients who were younger than 20 years of age or older than 90 years of age
96	were excluded. TCR provides complete and high quality information on cancer medical
97	records in Taiwan [10]. The data in the database has been de-identified, making it impossible
98	to identify the subjects. Our study used data from TCR including gender, date of diagnosis,
99	age at diagnosis, PCa stage, prostatic specific antigen (PSA), and Gleason's score. PSA value
100	was divided into five levels: <4, 4-9, 10-19, 20-50 and >50 ng/ml. Gleason's score also was
101	divided into five levels, ≤ 6 , 3+4, 4+3, 8 and 9-10. Gleason's score 3+4 indicates the primary
102	pattern was 3 and the secondary pattern was 4. In contrast, 4+3 means the primary pattern was
103	4 and the secondary pattern was 3.
104	The survival status of patients was verified by linkage with the National Mortality Registry.
105	All patients were followed until the end date of follow-up, the date of death or December 31,
106	2019, whichever came first. Survival function was generated via the Kaplan-Meier method
107	until the end of follow-up. LE was estimated by a semiparametric survival extrapolation

108	method, which was proposed by Hwang and Wang [8-9]. This method has been applied to
109	various diseases such as rheumatoid Arthritis [11], dialysis [12-13], schizophrenia [14] and
110	cancer [15]. Based on the life table of the National Vital Statistics of Taiwan, a reference
111	group matching the age, sex and calendar year of PCa patients was generated by the Monte
112	Carlo method. Assuming that the survival rate of the reference group was better than patients,
113	the survival ratio between the patients and the reference group was logit-transformed each
114	month. The survival rate of patients for the next month could be predicted by fitting restricted
115	cubic spline models. Further extrapolation of survival rate was predicted by using a rolling
116	extrapolation algorithm. Assuming the survival prediction for the next month was true and
117	ignoring the data of the first month used in the previous prediction, do the prediction again
118	until the survival rate approaches zero. The area under the survival curve of patients was
119	defined as LE. Besides, the difference of LE between the patients and the reference group
120	represents loss of LE. Loss of LE could be used as a measure of life loss because of disease.
121	The health care expenditures of each patient were confirmed by linkage with the national
122	health insurance reimbursement database. The monthly average cost was calculated by adding
123	the monthly costs of all patients, including the costs of inpatient and outpatient, and dividing
124	by the number of these patients who were still alive in each month. Assuming that the
125	patient's health care expenditures increase in the months before death, the average cost
126	function is estimated by weighting the average cost of the patient's months before death.

127	Lifetime cost can be calculated via the monthly average cost function multiplied by the
128	monthly survival function. Annual national health insurance expenditures were adjusted based
129	on the 2019 Consumer Price Index and the exchange rate (1 USD = 30.93 TWDs), and then
130	the estimated costs were adjusted at the annual discount rate (3%). The estimates of LE and
131	lifetime costs were calculated by the free R package iSQoL2, and the study was reviewed and
132	approved by the institutional review board of Tungs' Taichung MetroHarbor Hospital (IRB
133	number:110034). The need for participant informed consent was waived by the ethics
134	committee.
135	
136	

137 **Results**

138	A total of 30,207 patients with PCa were included in the study. Table 1 summarized the
139	estimated LE, loss of LE, lifetime cost and mean cost per year stratified by age and stage.
140	Survival curves of stages 1 to 3 were similar or even better than the matched reference group,
141	which violated the assumption of LE estimation method that the survival rate of the patients
142	should be worse than the reference group. Therefore, the LE and lifetime cost of those groups
143	could not be estimated. In stage 4, the loss of LE for the 20-64 age groups was the highest at
144	13.63 years, while the loss of LE for the 75-89 age groups was the lowest at 3.87 years. As for

145	the lifetime cost, the 20-64 age group is the highest, with 84,089 US dollars, while the 75-89
146	age group is the lowest, with 35,841 US dollars. The results were similar in the mean cost per
147	year, with \$9,893 for the 20-64 age group and \$4,573 for the 75-89 age groups.
148	
149	
150	
151	
152	
153	
154	
155	
156	
157	
158	
159	Table 1. Estimation of life expectancy, loss of life expectancy, lifetimes cost (USD) and
160	means cost per year for prostate cancer, stratified by age and stage.

Age	Age Stage	ige N	No. of	Δσρ*	LE (SE)	Loss of LE	Lifetime	Cost per
group	Juge	N	death		#	(SE)	cost (SE)	year
20-64								
	Stage 1	1,016	39 (3.84%)	60.5± 4.03	-	-	-	-
	Stage 2	2,733	137 (5.01%)	60.34 ±3.97	-	-	-	-
	Stage 3	718	53 (7.38%)	60.54 ±3.91	-	-	-	-
	Stage 4	1,652	732 (44.31%)	59.95 ±4.2	9.22 (1.36)	13.63 (1.36)	84,089 (5,957)	9,893
65-74	Stage 1	1,413	139 (9.84%)	69.92 ±2.83	-	-	-	-
	Stage 2	5,057	631 (12.48%)	70.2± 2.9	-	-	-	-
	Stage 3	1,594	210 (13.17%)	70.42 ±2.79	-	-	-	-
	Stage 4	3,173	1,445 (45.54%)	70.44 ±2.9	8.29 (0.48)	6.75 (0.48)	68,109 (2,825)	8,690
75-89								
	Stage 1	1,053	335 (31.81%)	80.38 ±3.88	-	-	-	-
	Stage 2	5,093	1,742 (34.20%)	80.57 ±3.81	-	-	-	-
	Stage 3	1,681	606 (36.05%)	80.51 ±3.79	-	_	-	-
	Stage 4	5,024	3,268 (6505%)	81.48 ±3.96	4.58 (0.14)	3.87 (0.14)	35,841 (918)	4,573



164 expectancy, in year; loss of LE, loss of life expectancy

168	In Table 2, the patients were stratified by age and PSA value. The survival rate of level 4-9
169	and 10-19 ng/ml were similar or even better than the reference group so LE can't be
170	estimated, either. However, the group of <4 ng/ml has worse survival than the reference
171	group. We reviewed the medical history of those patients and the result showed that a higher
172	proportion of transurethral resection of prostate (TURP) was performed one year before
173	cancer diagnosis in this group (S1 Fig). The PSA value usually decreased after TURP [16], so
174	we think the PSA level can't represent the actual value in <4 level group. In other groups of
175	20-50 and >50 ng/ml, regardless of age group, the higher the PSA value, the lower of LE, the
176	greater loss of LE, and higher mean cost per year.
177	
178	

181

182 Table 2. Estimation of life expectancy, loss of life expectancy, lifetimes cost (USD) and

183 means cost per year for prostate cancer, stratified by age and prostatic specific antigen (PSA).

Age	PSA	N	No. of	Aco*	LE (SE)	Loss of LE	Lifetime	Cost per
group	(ng/dL)	N	death	760	#	(SE)	cost (SE)	year
20-64								
	- 1	coc	115	60.38	18.55	4.03	66,098	4 1 2 0
	< 4	080	(16.76%)	±3.78	(2.16)	(2.16)	(5,272)	4,139
	4-9	1,899	66 (3.49%)	59.98 ±4.00	-	-	-	-
	10-19	1,309	89 (6.8%)	60.38 ±3.84	-	-	-	-
	20-50	881	113 (12.83%)	60.59 ±3.79	17.85 (3.02)	4.49 (3.03)	82,336 (6,781)	5,250
65-74	>50	1,435	575 (40.07%)	60.18 ±4.03	9.16 (1.34)	13.51 (1.36)	82,887 (6,638)	9,648
0574			301	70.29	12.86	2 31	56 599	
	< 4	1,280	(23.52%)	±2.85	(1.06)	(1.05)	(3,215)	4,771
	4-9	2,735	244 (8.92%)	69.92 ±2.87	-	-	-	-
	10-19	2,384	261 (10.95%)	70.10 ±2.94	-	-	_	-
	20-50	1,909	342 (17.92%)	70.50 ±2.83	13.38 (1.29)	1.68 (1.29)	70,688 (4,082)	5,684
	>50	2,907	1,205 (41.45%)	70.49 ±2.87	8.87 (0.57)	6.18 (0.57)	69,031 (2,967)	8,237
75-89								
	< 4	1,500	661 (44.07%)	81.26 ±4.07	7.18 (0.37)	1.47 (0.38)	32,892 (1,207)	4,709
	4-9	1,700	479 (28.18%)	79.93 ±3.71	-	-	-	-
	10-19	2,214	697 (31.48%)	80.28 ±3.73	-	_	-	-
	20-50	2,395	964 (40.25%)	80.75 ±3.81	7.53 (0.34)	1.33 (0.34)	43,763 (1,624)	5,938
	>50	4,808	2,918 (60.69%)	81.45 ±3.95	4.74 (0.16)	3.78 (0.16)	36,005 (833)	7,657

184

185 *Age	e presented as mean±standard	deviation; #	#SE, standard	error of the r	mean; LE, Life
----------	------------------------------	--------------	---------------	----------------	----------------

186 expectancy, in year; loss of LE, loss of life expectancy

188	Table 3 outlined the estimated LE, loss of LE, lifetime cost and mean cost per year stratified
189	by age and Gleason's Score. The groups of Gleason's Score ≤ 6 and 3+4 could not estimate
190	their LE and lifetime cost also because of similar or even better survival. Regardless of age
191	group, the group of Gleason's Score 9-10 had the greatest loss of LE. The highest lifetime
192	cost was the group of Gleason's Score 8. However, the highest mean cost was the group of
193	Gleason's Score 9-10.
194	
195	
196	
197	
198	
199	Table 3. Estimation of life expectancy, loss of life expectancy, lifetimes cost (USD) and
200	means cost per year for prostate cancer, stratified by age and Gleason's score.

Age	Gleason's	N	No. of	∆ go*	LE (SE)	Loss of LE	Lifetime	Cost per
group	score	IN	death	Age	#	(SE)	cost (SE)	year
20-64								
	< 6	2 1 1 2	102	60.25				
	20	2,110	(4.82%)	±3.87				
	3+1	۵۵۵	63	60.26				
	514	555	(6.31%)	±3.94				
	4+3	816	96	60.25	16.91	5.75	77,071	5 068
	415	010	(11.76%)	±3.92	(3.4)	(3.42)	(7,569)	5,000
	8	827	143	60.3±	16.75	5.84	91,875	6 23/
	0	027	(17.29%)	3.82	(2.15)	(2.15)	(6,472)	0,234
	0_10	1 1 5 1	454	60.24	10.1	12.52	79,800	8 565
	9-10	1,191	(39.44%)	±4.03	(1.48)	(1.47)	(6,667)	8,505
65-74								
	< 6	2 2/6	348	70.04				
	20	5,540	(10.4%)	±2.89				
	2 . /	1 9/0	250	70.19				
	574	1,049	(13.52%)	±2.88	-	-	-	-
	1.2	1 700	294	70.39	13.3	1.8	66,139	E 22E
	4+5	1,700	(17.29%)	±2.87	(1.56)	(1.56)	(4,099)	5,555
	o	1 602	374	70.3±	11.63	3.51	73,643	6 7/9
	0	1,002	(23.35%)	2.83	(1.35)	(1.35)	(4,930)	0,740
	0.10	2 216	902	70.48	10.01	5.03	70,173	7 5 1 0
	9-10	2,510	(38.95%)	±2.9	(0.82)	(0.83)	(3 <i>,</i> 750)	7,546
75-89								
	<	2 602	818	80.32				
	20	2,095	(30.38%)	±3.81				
	2 . /	1 72/	615	80.39				
	574	1,734	(35.47%)	±3.74	-	-	-	-
	4.2	1 007	805	80.67	7.23	1.69	42,540	E 094
	4+5	1,997	(40.31%)	±3.8	(0.47)	(0.47)	(1,857)	5,964
	0	2.045	912	80.98	7.2	1.56	43,089	6 1 5 2
	0	2,045	(44.6%)	±3.96	(0.35)	(0.36)	(1,802)	0,152
	0.10	2 100	2,085	81.43	5.2	3.32	38,175	7 402
	9-10	5,408	(60.12%)	±3.92	(0.22)	(0.22)	(1,159)	7,483

- *Age presented as mean±standard deviation; #SE, standard error of the mean; LE, Life
- 203 expectancy, in year; loss of LE, loss of life expectancy

204

205

206 **Discussion**

208	This study estimated the LE, loss of LE, and lifetime health care costs of PCa. LE was
209	estimated by a semiparametric survival extrapolation method, which was proposed by Hwang
210	and Wang [9-10]. This method has been applied to various diseases such as rheumatoid
211	arthritis [11], dialysis [12-13], schizophrenia [14] and cancer. It is the first time it has been
212	used to analyze the LE of PCa. The LE (shown in Table 1) of stages 1 to 3 PCa were similar
213	or even better than the matched reference group. The same result can be observed when LE,
214	loss of LE and lifetime healthcare costs has been stratified by age and PSA or age and
215	Gleason's score (shown in Table 2, 3). There are some possible explanations. First, the early
216	stage PCa has a good prognosis under the care of Taiwan's national health system. The
217	majority of the treatment can be subsidized by the national health system. Early-stage PCa
218	does not affect a patient's average LE. There is no significant difference in the statistics of LE
219	between stages 1-3 of PCa, whether in the 20-64 year old group or the 75-89 year old group.

220	Second, being diagnosed with cancer raises awareness of a patient's own health. Patients
221	become more conscious of their health after being diagnosed with PCa. They also come to the
222	hospital more often for follow-up of PCa, and if they have other health problems, they will be
223	found earlier.
224	Our study also revealed another characteristic of PCa in Taiwan: a high proportion of
225	synchronous metastatic PCa across all three age stratification. Synchronous metastatic PCa
226	accounts for 27% in age group 20-64, 28.2% in age group 65-74, and 39% in age group over
227	75, respectively. Among all newly diagnosed PCa patients, Taiwan exhibits a considerably
228	high rate of synchronous metastatic PCa when compared to the United States. (32% vs. 5%).
229	[18] Based on the data presented, it's evident that a significant number of Taiwanese PCa
230	patients receive late-stage diagnoses. Early detection of PCa has the potential to substantially
231	decrease the incidence of synchronous metastatic PCa in Taiwan.
232	Health care expenditures are crucial for shaping national health policy and allocating public
233	health resources within a finite budget. Early detection of PCa through PSA screening and
234	digital rectal examination may allow for early disease stratification, thereby improving
235	disease prognosis and enabling treatment before disease progression. Our data (Table 1)
236	support this point of view: there is no significant difference in the statistics of LE, loss of LE,
237	and lifetime health care costs between stages 1-3 of PCa. In end-stage PCa, it causes a loss of
238	LE by 13.63, 6.75, and 3.87 years in the 20-64, 65-74, and 75-89 age groups, respectively.

239	The lifetime cost of end-stage PCa is \$84,089, \$68,109 and \$35,841 in the 20-64, 65-74, and
240	75-89 age groups, respectively. In Table 2, the annual cost for PCa stratification by PSA level
241	can be observed across all three age stratifications (\$9,648, \$8,237 and \$7,657, respectively).
242	Early detection of PCa can save patients from experiencing a loss of LE and reduce the total
243	lifetime cost and national health care expenditures.
244	PCa is the fifth leading cause of cancer-related deaths in Taiwan. However, routine PSA
245	screening is not standard in Taiwan. There remains controversy of PSA screening for PCa
246	within countries. Currently, only the five major cancers in Taiwan, namely colorectal cancer,
247	oral cancer, cervical cancer, lung cancer, and breast cancer, have screening plans subsidized
248	by the government. Taiwan's national health system disapproves of population-wide PSA
249	screening programs for PCa. The lower incidence and mortality rate of PCa in Taiwan
250	compared to those in Europe and the United States is a major reason for this decision. The
251	health-care authority considers population-wide PSA screening to have low
252	cost-effectiveness. Apart from this, the government has ignored the characteristics of PCa in
253	Taiwan: a high proportion of synchronous metastatic PCa compared with other developed
254	countries. On the other hand, unnecessary PSA screening might cause overdiagnosis and
255	overtreatment, doing more harm than benefits to the patients [16]. The Taiwan Urological
256	Association recommends early PSA testing only in male aged more than 50 year-old or male
257	more than 45 year-old with family history of PCa. However, early PCa has few symptoms and

258	is often diagnosed as advanced PCa while symptomatic. As a result, many men diagnosed
259	with PCa never know they have the disease unless they undergo an examination. To make
260	matters worse, Taiwan's national health care system does not cover approaches like Magnetic
261	Resonance Imaging and biomarkers, such as the Prostate Health Index, for the diagnosis of
262	PCa.
263	Taiwan has had a national health insurance system since 1995, covering most of the medical
264	expenses for PCa patients. This coverage extends from treatment modalities of radical
265	prostatectomy, internal or external radiation therapy in the localized cancer, to androgen
266	deprivation therapy, second-generation antiandrogens, and chemotherapy in the advanced
267	stage of the disease. However, the nature of social welfare, universal cost coverage of national
268	health insurance also places a heavy economic burden on itself. The increasing incidence and
269	mortality rate of PCa make it a critical public health issue, posing a great economic burden on
270	the national health system. Despite the growing number of therapies and treatments for PCa,
271	it is associated with substantial societal costs and healthcare expenses. These costs are
272	expected to rise with the incorporation of novel and more expensive technologies for
273	managing PCa in the future. Early detection and treatment of PCa can contribute to reducing
274	overall PCa medical costs. This is particularly relevant for the considerable medical costs
275	associated with synchronous metastatic PCa. If the national healthcare system were to initiate
276	strategies such as the introduction of a PSA screening program, it could further decrease

- 277 overall PCa costs and healthcare expenditures. This approach becomes especially crucial in
- 278 Taiwan, where a high rate of synchronous metastatic PCa has been recorded.
- 279 The strength of our study lies in its nationwide cohort and long-term follow-up period. The
- 280 data were obtained from the TCR database, which provides exhaustive, complete and high
- 281 quality information on cancer medical records in Taiwan. Although, the limitation is that the
- study is inherently retrospective. Second of all, the total cost cannot exclude the cost caused
- by other diseases.
- 284 In conclusion, this study provides real-world evidence to support early detection of PCa can
- save LE and decrease the total cost burden on the healthcare system. The results of this study
- 286 contribute to better national healthcare resource allocation and policy decisions in PCa
- treatment. Furthermore, it also raises awareness and public concern about PCa and highlights

its impact on the people of Taiwan, both in terms of loss of LE and lifetime cost.

289

290 **Conclusions**

291 This study provides real-world evidence to support health care policy-making and clinical

- decisions regarding PCa. Due to the high proportion of synchronous metastatic PCa in
- 293 Taiwan, the findings of this analysis emphasize the importance of early detection of PCa,
- which can save LE and decrease the total cost burden on the healthcare system.

295

296 Acknowledgements

297 Collection and assembly of data: Ya-Chu Yang

298

299 **Reference**

300	1.	Global Burden of Disease Cancer Collaboration. Global, Regional, and National
301		Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and
302		Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic
303		Analysis for the Global Burden of Disease Study. JAMA Oncol. 2019;5(12):1749-
304		1768.
305	2.	Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020
306		Jan;70(1):7-30
307	3.	Statistics of cause of death ministry of health and warfare. 2019.
308		https://www.mohw.gov.tw/lp-4650-2.html
309	4.	Kimura, Takahiro, and Shin Egawa. "Epidemiology of prostate cancer in Asian
310		countries." International journal of urology : official journal of the Japanese
311		Urological Association vol. 25,6 (2018): 524-531.

312	5.	Gustavsen G, Gullet L, Cole D, Lewine N, Bishoff JT. Economic burden of illness
313		associated with localized prostate cancer in the United States. Future Oncol.
314		2020 Jan;16(1):4265-4277.
315	6.	Smith-Palmer, J., Takizawa, C. & Valentine, W. Literature review of the burden of
316		prostate cancer in Germany, France, the United Kingdom and Canada. BMC Urol
317		19, 19 (2019)
318	7.	Withrow D, Pilleron S, Nikita N, Ferlay J, Sharma S, Nicholson B, et al. Current and
319		projected number of years of life lost due to prostate cancer: A global study.
320		Prostate. 2022 Aug;82(11):1088-1097.
321	8.	Hwang JS, Wang JD. Monte Carlo estimation of extrapolation of quality-adjusted
322		survival for follow-up studies. Stat Med. 1999;18(13):1627-40.
323	9.	Hwang JS, Hu TH, Lee LJ, Wang JD. Estimating lifetime medical costs from
324		censored claims data. Health Econ. 2017;26(12):e332-e44.
325	10	. Chiang CJ, You SL, Chen CJ, Yang YW, Lo WC, Lai MS. Quality assessment and
326		improvement of nationwide cancer registration system in Taiwan: a review. Jpn J
327		Clin Oncol. 2015;45(3):291-6.
328	11.	. Chiu YM, Lu YP, Lan JL, Chen DY, Wang JD. Lifetime Risks, Life Expectancy, and
329		Health Care Expenditures for Rheumatoid Arthritis: A Nationwide Cohort

- 330 Followed Up From 2003 to 2016. Arthritis Rheumatol. 2021;73(5):750-8.
- 331 12. Kao TW, Huang JW, Hung KY, Chang YY, Chen PC, Yen CJ, et al. Life expectancy,
- expected years of life lost and survival of hemodialysis and peritoneal dialysis
- 333 patients. J Nephrol. 2010;23(6):677-82.
- 13. Kao TW, Chang YY, Chen PC, Hsu CC, Chang YK, Chang YH, et al. Lifetime costs for
- peritoneal dialysis and hemodialysis in patients in Taiwan. Perit Dial Int.
- 336 2013;33(6):671-8.
- 337 14. Lêng CH, Chou MH, Lin SH, Yang YK, Wang JD. Estimation of life expectancy,
- 338 loss-of-life expectancy, and lifetime healthcare expenditures for schizophrenia in
- 339 Taiwan. Schizophr Res. 2016;171(1-3):97-102.
- 340 15. Wu TY, Chung CH, Lin CN, Hwang JS, Wang JD. Lifetime risks, loss of life
- 341 expectancy, and health care expenditures for 19 types of cancer in Taiwan. Clin
- 342 Epidemiol. 2018;10:581-91.
- 343 16. Fonseca RC, Gomes CM, Meireles EB, Freire GC, Srougi M. Prostate specific
- 344 antigen levels following transurethral resection of the prostate. Int Braz J Urol.
- 345 2008;34(1):41-8.
- 346 17. Cabarkapa S, Perera M, McGrath S, Lawrentschuk N. Prostate cancer screening
- 347 with prostate-specific antigen: A guide to the guidelines. Prostate Int. 2016

348 Dec;4(4):125-129.

- 18. Siegel DA, O'Neil ME, Richards TB, Dowling NF, Weir HK. Prostate Cancer
- 350 Incidence and Survival, by Stage and Race/Ethnicity United States, 2001-2017.
- 351 MMWR Morb Mortal Wkly Rep. 2020 Oct 16;69(41):1473-1480.

352

353 Supporting information

- 354 S1 Figure The proportion of PCa patients who underwent TURP one year before PCa
- 355 diagnosis.